TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06295731: A Phase 2/3, Randomized Study of Ordastobart (INBRX-106) Plus Pembrolizumab vs Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic HPV-positive Oropharyngeal Squamous Cell Carcinoma Expressing

Sponsor: Inhibrx Biosciences, Inc · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 450 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,367,288

Rescue Site Savings

+$1,578,192

Unlock Full NCT06295731 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06295731 Rescue Dossier →